Physician profile
Scott Yager
NPI 1669522595
$4,611.20
in general payments reported to CMS, 2019-2025
35 companies · $382 in 2025
The $382 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $849 · 2020: $750 · 2021: $982 · 2022: $622 · 2023: $598 · 2024: $427 · 2025: $382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,407.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $897.62 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $641.79 | 2021-2024 | Qulipta, Ubrelvy, Vraylar |
| Lilly USA, LLC | $580.70 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $409.44 | 2019-2025 | |
| Amarin Pharma, INC. | $264.67 | 2019-2022 | |
| Amgen INC. | $253.44 | 2019-2025 | Otezla, Repatha, Repatha |
| Allergan, INC. | $212.15 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $132.91 | 2019-2025 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $120.36 | 2019-2022 | |
| Abbott Laboratories | $117.54 | 2021-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $104.33 | 2019-2022 | |
| Glaxosmithkline, LLC. | $96.64 | 2019-2025 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $90.77 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $85.00 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.09 | 2019-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $51.73 | 2019-2025 | Lagevrio |
| Arbor Pharmaceuticals, INC. | $51.70 | 2020-2021 | |
| Eisai INC. | $48.52 | 2020-2021 | |
| Genentech, INC. | $39.95 | 2019 | |
| Boston Scientific Corporation | $34.97 | 2022 | |
| Exact Sciences Corporation | $30.11 | 2023-2024 | Cologuard Collection Kit |
| Dexcom, INC. | $29.97 | 2024-2025 | Dexcom G6 Transmitter |
| Ferring Pharmaceuticals INC. | $28.22 | 2023 | Rebyota |
| Novartis Pharmaceuticals Corporation | $27.10 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $27.02 | 2022-2024 | Quviviq |
| Daiichi Sankyo INC. | $26.14 | 2021-2024 | Injectafer |
| Genzyme Corporation | $20.01 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $19.71 | 2025 | Rexulti |
| Bardy Diagnostics, INC. | $15.00 | 2021 | |
| Cti Biopharma Corp. | $14.38 | 2023 | Vonjo |
| Paratek Pharmaceuticals, INC. | $13.76 | 2025 | Nuzyra |
| Kowa Pharmaceuticals America, INC. | $12.08 | 2020 | |
| Collegium Pharmaceutical, INC. | $11.73 | 2021 | |
| Astellas Pharma US INC | $11.34 | 2019 | |
| Aytu Biopharma, INC. | $11.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Yager listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.